Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2017

View Archived Issues

DerG-PG70 LEAPS vaccine suppresses arthritis progression in two Th1 cell-driven murine models

Exenatide has positive effects on motor scores in patients with Parkinson's disease

Promising preclinical data for novel pan-MMP inhibitor-based tracer [99mTc]RYM-1

Cambridge Epigenetix and NuGEN partner to combine leading technologies in epigenetics research

First patient enrolled in phase I study of OTS-167 in breast cancer

Aradigm receives grant to study products in pulmonary non-tuberculous mycobacteria

Medshine Discovery, Jiangsu Chia Tai Tianqing Pharmaceutical patent bile acid receptor agonists

Prometic Life Sciences finalizes joint venture with affiliates of Shenzhen Royal Asset Management

Context Therapeutics enters into collaboration agreements to study Sigma1 protein

Protalex awarded grant to support development of PRTX-100

First patient dosed in phase I/II study of birinapant in combination with Keytruda in solid tumors

Medivir licenses exclusive rights for MIV-802 to Ascletis in greater China

ViraCyte receives CPRIT grant from the Cancer Prevention and Research Institute of Texas

Tetraphase Pharmaceuticals submits marketing application for i.v. eravacycline in Europe

FDA approves Besponsa for adults with relapsed or refractory ALL

First patient dosed in phase I study of UCART-123 in BPDCN

Avadel and Serenity enter into exclusive negotiations for Noctiva

FDA grants new ovarian cancer approvals for Lynparza

Gilead Sciences Canada receives approval notice for Vosevi in refractory HCV

Response submitted to FDA's complete response letter for latanoprostene bunod

Health Canada approves Maviret for chronic HCV in all major genotypes

Hikma expands licensing agreement with Takeda for new products in the Middle East and North Africa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...